Idorsia Ltd
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04819464
- Locations
- π΅πΉ
BlueClinical Phase 1 Hospital de Prelado, Porto, Portugal
ππΊCRU Hungary, Kistarcsa, Hungary
A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects
- Conditions
- Interventions
- Drug: ACT-777991 (SAD)Drug: ACT-777991 (MAD)Drug: 14C-ACT-777991 microtracer (MAD - ADME)Drug: 14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)Drug: Placebo (SAD)Drug: Placebo (MAD)Drug: Microtracer matching placebo (SAD - Absolute Bioavailability)Drug: Microtracer matching placebo (MAD - ADME)
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT04798209
- Locations
- π³π±
QPS Netherlands B.V., Groningen, Netherlands
Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 136
- Registration Number
- NCT04753164
- Locations
- πΊπΈ
NeuorTrials Research Inc, Atlanta, Georgia, United States
πΊπΈCollaborative Neuroscience Network (CNS), Garden Grove, California, United States
πΊπΈWr-Pri, Llc, Encino, California, United States
A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT04608513
- Locations
- π©πͺ
Parexel International GmbH Klinikum Westend, Berlin, Germany
A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04557280
- Locations
- πΊπΈ
Altasciences Clinical Kansas, Inc, Overland Park, Kansas, United States
Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 226
- Registration Number
- NCT04470713
- Locations
- πΊπΈ
Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States
πΊπΈAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
π§π·Hospital de ClΓnicas de Porto Alegre - HCPA, Porto Alegre, Brazil
A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT04452006
- Locations
- π©πͺ
Parexel International GmbH, Berlin, Germany
The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04406896
- Locations
- π©πͺ
CRS Clinical Research Services, Kiel, Germany
A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04390334
- Locations
- π©πͺ
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04286750
- Locations
- π΅πΉ
BlueClinical Phase 1 Hospital de Prelado, Porto, Portugal